News About: Pharm. Affairs
‘Unnecessary’ to ease current regulation about direct purchase of drugs
When it came to a part of opinions to ease the current regulation for an individual to directly bring purchased pharmaceutical products from foreign countries to Korea, a number of Koreans raised concerns.
According ...
“Lecture and consulting fees will be KRW 500,000 per case and KRW 3 million per year”
It is expected lecture and consulting fees will be accepted on KRW 500,000 per case and KRW 3 million per year in principle, and KRW 5 million per year will also be accepted depending on their capability and specialty...
Boycott wave against Oxy in medical and pharmacy fields
While the boycott across the nation against Oxy Reckitt Benckiser, the biggest assailant of the humidifier germicide death case, is spreading, the medical and pharmacy fields have also started to join in it.
Targets...
Medium-sized DongKwang Pharm successfully avoids KRW 10 billion ‘Cancidas’ patent
A medium pharmaceutical company DongKwang Pharmaceutical raised a chance for the early launch of Cancidas(caspofungin acetate, MSD Korea), antifungal, through avoiding its patent alone.
Since it is the patent other c...
A series of defeats by domestic pharmaceuticals in patent challenges
Domestic pharmaceutical companies were defeated from patent suits in series. They were against substance patents of Ezetrol(ezetimibe), Forxiga(dapagliflozin) and Pradaxa(dabigatran etexilate) and a crystalline patent...
New Baxalta drug emerges in Pfizer-monopolizing hemophilia B market
In the domestic hemophilia B(congenital factor ix deficiency) market which had been monopolized by Pfizer with Benefix, a rival emerged.
Recently, the Ministry of Health and Welfare(MOHW) administratively notified t...
Will the humidifier germicide death case fuel boycotts against Gaviscon and Strepsils?
Criticism on RB Korea(Oxy Reckitt Benckiser) which was indicated to generate the highest number of victims at the humidifier germicide death case has widely spread.
In the circumstance, the pharmacy world which dea...
‘2 Strong’ system in entecavir market, led by Dong-A and Bukwang
In the market of entecavir(product name: Baraclude), one of the last year’s largest issues in the patent expiration field, Dong-A ST and Bukwang Pharm have formed a 2-stong competition.
For the 3rd position, Hanmi P...
Pharmacies shocked by move to ease regulation for foreign pharmaceutical purchases
Since a move to ease the current Pharmaceutical Affairs Law to restrict direct purchases of pharmaceutical products in a foreign country by an individual has been visualized, the pharmacy world is expected to strongly...
Insurance benefits will be applied for Sovaldi and Harvoni this May
While a group infection of hepatitis C has recently been controversial, new hepatitis C treatments will be applied by the health insurance benefit from this May.
Through the Amendment to the ‘Drug Benefit List and C...
